1. Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy
by Gabriel Etienne, Nicolini E Nicolini, Stéphanie Dulucq, Anna Schmitt, Sandrine Hayette, Éric Lippert, Isabelle Tigaud, Stephane Morisset, Caroline Bureau, Didier Adiko, Gerald Marit, Josy Reiffers, and Francois-Xavier Mahon
Blood
Volume 120(21):
November 16, 2012
©2012 by American Society of Hematology

2. Event-free survival of patients who achieved CCyR without MMR (n=23) (CCyR+MMR-), CCyR with MMR without CMR (n=92) (CCyR+MMR+CMR-) and CCyR with CMR (n=65) (CCyR+MMR+CMR+) on IM therapy.
Event-free survival of patients who achieved CCyR without MMR (n=23) (CCyR+MMR-), CCyR with MMR without CMR (n=92) (CCyR+MMR+CMR-) and CCyR with CMR (n=65) (CCyR+MMR+CMR+) on IM therapy.
Gabriel Etienne et al. Blood 2012;120:3754
©2012 by American Society of Hematology

3. Progression-free survival of patients who achieved CCyR without MMR (n=23) (CCyR+MMR-), CCyR with MMR without CMR (n=92) (CCyR+MMR+CMR-) and CCyR with CMR (n=65) (CCyR+MMR+CMR+) on IM therapy.
Progression-free survival of patients who achieved CCyR without MMR (n=23) (CCyR+MMR-), CCyR with MMR without CMR (n=92) (CCyR+MMR+CMR-) and CCyR with CMR (n=65) (CCyR+MMR+CMR+) on IM therapy.
Gabriel Etienne et al. Blood 2012;120:3754
©2012 by American Society of Hematology